Sam Brusco, Associate Editor03.14.22
Dexcom has secured a CE mark for its Dexcom G7 continuous glucose monitoring (CGM) system for patients with diabetes aged two years and up, including pregnant women.
Dexcom G7, according to the company, warms up faster than any other CGM on the market. It sends real-time glucose readings automatically to a compatible smart device or receiver without the need for fingersticks. A suite of customizable alerts can warn of high or low glucose levels to help users spend more time in range.
“Today marks an incredible milestone for our company and for people with diabetes in Europe,” Kevin Sayer, chairman, president and, CEO of Dexcom told the press. “This all-new platform offers an incredibly powerful CGM that is simple to use, providing our users with insightful glucose data on one screen that helps them spend less time managing diabetes and more time doing the things they love. Dexcom G7 takes everything people love about G6 and makes it even better.”
The company is also collaborating with insulin pump partners to integrate G7 into current and future automated insulin pumps.
“Over the past 20 years, Dexcom has been one of the leaders and pioneers in advancing real-time CGM technology,” said Professor Partha S. Kar, OBE, national specialty advisor, Diabetes at NHS England and consultant endocrinologist at Portsmouth Hospitals NHS Trust. “With enhanced features and added simplicity, Dexcom G7 will hopefully make diabetes management easier for both patients and their healthcare providers, something that is especially important as we see more and more evidence of the benefits of CGM in broader populations of those living with diabetes.”
Dexcom plans to launch the G7 in Europe over the next few weeks. The firm also aims to introduce an updated CGM algorithm this year.
The company submitted a 510(k) notification to the U.S. Food and Drug Administration (FDA) in Q4 of last year. Dexcom recently reported fiscal 2021 revenue of $2.54 billion.
Dexcom G7, according to the company, warms up faster than any other CGM on the market. It sends real-time glucose readings automatically to a compatible smart device or receiver without the need for fingersticks. A suite of customizable alerts can warn of high or low glucose levels to help users spend more time in range.
“Today marks an incredible milestone for our company and for people with diabetes in Europe,” Kevin Sayer, chairman, president and, CEO of Dexcom told the press. “This all-new platform offers an incredibly powerful CGM that is simple to use, providing our users with insightful glucose data on one screen that helps them spend less time managing diabetes and more time doing the things they love. Dexcom G7 takes everything people love about G6 and makes it even better.”
The company is also collaborating with insulin pump partners to integrate G7 into current and future automated insulin pumps.
“Over the past 20 years, Dexcom has been one of the leaders and pioneers in advancing real-time CGM technology,” said Professor Partha S. Kar, OBE, national specialty advisor, Diabetes at NHS England and consultant endocrinologist at Portsmouth Hospitals NHS Trust. “With enhanced features and added simplicity, Dexcom G7 will hopefully make diabetes management easier for both patients and their healthcare providers, something that is especially important as we see more and more evidence of the benefits of CGM in broader populations of those living with diabetes.”
Dexcom plans to launch the G7 in Europe over the next few weeks. The firm also aims to introduce an updated CGM algorithm this year.
The company submitted a 510(k) notification to the U.S. Food and Drug Administration (FDA) in Q4 of last year. Dexcom recently reported fiscal 2021 revenue of $2.54 billion.